CXCL8 and intrahepatic cholangiocarcinoma: Targeted inhibition of ALDH1A1, IL-8, or NF-κB signaling pathway activity can effectively suppress the proliferation, invasion, migration, and stemness of ICC, providing new insights for treatment.